Early Palliative Care Improves Quality of Life in NSCLC

This article originally appeared here.
Share this content:
Early Palliative Care Improves Quality of Life in NSCLC
Early Palliative Care Improves Quality of Life in NSCLC

(HealthDay News) – Early palliative care for patients with terminal non-small-cell lung cancer (NSCLC) improves the timing of final chemotherapy administration and is associated with an earlier transition to hospice care, according to a study published online December 27 in the Journal of Clinical Oncology.

Joseph A. Greer, MD, of the Massachusetts General Hospital Cancer Center in Boston, and colleagues investigated whether early palliative care affected the frequency and timing of chemotherapy use and hospice care for patients with metastatic NSCLC. This 18-month study involved 151 tertiary-care patients with newly diagnosed metastatic NSCLC who were randomized to receive either early palliative care integrated with standard oncology care or standard oncology care alone. Measures of outcome included the number and types of chemotherapy regimens, and the frequency and timing of chemotherapy administration and hospice referral.

Although the total number of chemotherapy regimens did not differ between the groups, the researchers found that patients receiving early palliative care in addition to standard oncology care were half as likely to receive chemotherapy within 60 days of death as those receiving standard oncology care alone. Additionally, the median interval between the last chemotherapy dose and death was about 24 days longer for those patients who received early palliative care. Although rates of referral to hospice did not differ between the groups, patients receiving palliative care had a higher rate of hospice care for longer than one week prior to death than those not receiving palliative care.

"By reducing intravenous chemotherapy use in the final months of life, patients assigned to early palliative care were able to access hospice services sooner than those in the standard-care group and had durations of enrollment longer than one week before death, which is a clinically meaningful measure for quality end-of-life care. The innovative model of palliative care integrated into the outpatient setting soon after diagnosis of terminal cancer provides an alternate and efficacious approach to reconcile the needs of patients for symptom management and psychosocial support while simultaneously undergoing anticancer therapy," the authors write.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs